In conclusion, our study revealed statistical associations between PRKDC expression and clinical outcome, genetic mutation, protein phosphorylation, immune cells infiltration, immune checkpoints, TMB, and MSI across pan-cancers, and confirmed PRKDC’s latent involvement in tumor immunology and as a therapeutic target and prognostic biomarker. The gene discussed is PRKDC; the disease is neoplasm.